Endostatin prevents abnormal blood vessel growth

Article

A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye.

A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye, thereby offering a possible treatment for advanced age-related macular degeneration (AMD).

Alexander Marneros and co-workers from the Harvard Medical School, US and Niigata University Postgraduate School of Medicine, Japan tested the effects of endostatin on mice lacking the naturally occurring substance and in normal mice. The mice without endostatin were found to be three times more likely to develop advanced AMD than normal mice.

The researchers concluded that endostatin functions as the body's own natural inhibitor of new blood vessel growth and thus presents a possible therapeutic option for macular degeneration.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.